Posted in Oncology, Pharma News, tagged leukemia on August 11, 2011|
Yes, it’s still early – but research results like this make me do a happy dance!!!
_________
Impactiviti is the Pharmaceutical Connection Agency. As the eHarmony of sales/training/marketing, we help our pharma/biotech clients find optimal outsource vendors for training, eMarketing, social media, and more.
Learn more about our free services here
_________
Sign up for the Impactiviti Connection weekly e-newsletter (see sample), chock full of news and resources for pharmaceutical professional
Posted in Bayer, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Social Media, Top News, tagged Bayer, Lantus, OncoMed, sanofi, Tasigna on June 18, 2010|
*****
TODAY’S NEWS:
Prostate cancer drug treatment (Sanofi) approved on the fast track. But – a warning flag for S-A about possible Lantus/cancer link.
Bayer and OncoMed to co-develop oncology drugs in new agreement.
Novartis‘ blood cancer drug Tasigna gets approval for earlier use with CML.
RECOMMENDED
SocialRx – pharma social media resources. A page full of goodies, newly updated from us here at Impactiviti. Enjoy!
PLUS
Sex pills for women. Count me among the skeptics. And, medical flops of the decade (from Forbes).
JUST FOR FUN
Just where in the world is that South Africa place??
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Amgen, BMS, Bristol Myers, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, Sales training, Top News, Training Needs, tagged Amgen, Gleevec, glivec, nanosponge, Novartis, prolia, Sprycel, Tasigna on June 4, 2010|
*****
Impactiviti Daily will not be published next week, as I will be attending the annual Society of Pharmaceutical and Biotech Trainers conference (SPBT) in Orlando.
TODAY’S NEWS:
As the pre-ASCO news heats up, the big headline will be leukemia treatments – specifically, BMS‘ Sprycel and Novartis‘ Gleevec and Tasigna (just in – Tasigna shown superior to Gleevec in slowing CML: 18-month results). Treatments in this class, by the way, are something near miracle drugs. They’ve totally revolutionized blood cancer treatments. In related news, Novartis’ Afinitor (approved for kidney cancer) meets goals in a trial for pancreatic cancer.
Why should you be interested in a “nanosponge”? Well, there’s this – Scientists have found that a delivery system based on a technique called nanosponge is three to five times more effective at reducing tumor growth than direct injection…more
Will Amgen‘s new osteoporosis drug Prolia find its true home in oncology treatment? – The company has also applied for FDA approval to market the drug to breast cancer and prostate cancer patients who are undergoing a hormone treatment that weakens their bones. What’s more, the company is conducting tests designed to show that Prolia prevents cancer from spreading to the bones — an indication that could push sales of the drug to as much as $6 billion annually, some analysts predict…more Also – huge sales force push for Prolia.
20% of high school students abuse prescription drugs. Wow – sobering.
RECOMMENDED
Simulations/Gaming. Live training simulations, digital sims (eLearning) and on-line games – our partner network has the expertise you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
How to reduce e-mail ping-pong. You know all that back-and-forth? Here’s a way to undercut it at the start!
JUST FOR FUN
See-through animals. Ten of them. Amazing.
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Avandia, Bristol Myers, Cephalon, Glaxosmithkline, GSK, Oncology, Pharma, Pharma News, Pharmaceutical, Sales training, Social Media, Training, Vendor Selection, tagged asco, Avandia, Cephalon, cibavision, iphone, nuvigil, PSA on June 3, 2010|
*****
TODAY’S NEWS:
Could low-dose Avandia be useful in preventing diabetes onset? This would be good news for GSK – GlaxoSmithKline Plc’s Avandia helped prevent the onset of diabetes when taken at a low dose with another drug, according to a company-sponsored study that suggests the regimen may help patients without raising heart attack risk. Half doses of Avandia and the therapy metformin, when combined, cut the risk of developing diabetes by two-thirds compared with placebo, Canadian researchers said..more
We’re in the gusher phase of the pre-ASCO press release flood. This sneak peek on BMS products is intriguing. More here – Four Scenarios for BMS.
Lying about data – people just don’t seem to learn. Sigh. And that goes for financial folks, politicians, climate scientists – it ain’t just pharma, folks!
Cephalon, Provigil and Nuvigil.
RECOMMENDED
Leadership Training. We’ve got the vendor/partners you need for this – field leaders or executive leadership level. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
New iPhone app released by Novartis subsidiary CibaVision. My “live” review while playing with it – mixed feelings. And, while we’re doing reviews – a north Jersey restaurant (Tabor Road Tavern) that blew me away.
JUST FOR FUN
Who needs PSA tests for prostate cancer when you have Fido? What’s interesting is that this is – amusingly – serious!
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in J&J, Johnson and Johnson, Oncology, Pharma, Pharma News, Pharmaceutical, Roche, tagged asco, HGH, Tamiflu on May 24, 2010|
*****
TODAY’S NEWS:
We’re in the pre-ASCO oncology news build-up phase. Here’s a brief preview. And even more here.
Does HGH really help athletes? Interesting article – the last paragraph is the kicker.
Whistleblowers (J&J) get a payday. And, allegations about illegal sales practices by Roche with Tamiflu.
RECOMMENDED
eLearning. We know that space inside and out, and we have great partners to recommend. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Karl Schmieder of MessagingLab interviews me about Impactiviti. Plus – the timing is never really “right,” is it? 29 and Counting.
JUST FOR FUN
If this doesn’t make you want to visit South America some day, nothing will!
AND, a pharma spoof – So, What’s your Problem with Gram-Negative Bacteria?
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Celgene, Cephalon, FDA, Oncology, Pharma, Pharma News, Pharmaceutical, Top News, tagged Celgene, Cephalon, Gilead, Gilena, MS, Novartis on April 13, 2010|
*****
TODAY’S NEWS
Hugely encouraging results for Novartis‘ new experimental (oral) MS treatment – Novartis’ Gilena has delivered an impressive performance in a Phase III trial in patients multiple sclerosis, cutting relapse rates by 62% in treatment-naïve patients and sustaining its effects for more than two years. Importantly, data from the two-year FREEDOMS study, presented at the American Academy of Neurology annual meeting, also showed that relapse rates were reduced by a significant 44% in patients who had previously been treated with other drugs for MS, highlighting the potential benefit of switching therapies…more
Gilead starts late stage testing of “4-in-1” HIV pill.
An interesting account of regulatory “unintended consequences.” How to make a cheap drug very expensive.
Cephalon hopes to gain more cheddar by adding some Swiss. Sorry – couldn’t resist…
Celgene: the new “big kid” on the block.
RECOMMENDED
Coaching Skills – The Impactiviti Partner Network is your resource if you’re looking to improve the coaching skills of your employees. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
An amusing patient health video made by J&J. Well worth 4 minutes of your time. The Appointment.
JUST FOR FUN
Oldie but goodie from The Onion – American to start charging fees to Non-passengers.
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Eli Lilly, Lilly, Oncology, Pharma, Pharma News, Pharmaceutical, Top News, tagged Byetta, Eli Lilly, hallucinogens on April 12, 2010|
*****
Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there!
For more information, including registration, please click here to visit the event website. Use promo code IMPACT for a discounted rate of $155.
TODAY’S NEWS
Lilly in an Indy pullback.
Taking another look at medical uses for hallucinogens. Timothy Leary would be proud!
Byetta (once-weekly) and possible cancer risks. Frankly, I have a bit of problem with this sort of stuff. When you pump rats with mega-doses of just about anything, what do you expect? Eternal life?
If you need a Monday morning dose of super-sized, complex words in a cloud of oncology verbiage, this one’s for you. Otherwise, nothing to see here…
RECOMMENDED
Selling Skills – We can recommend best-in-class partners and programs for your needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
JUST FOR FUN
Visual treat – Steel Giants floating on a blanket of Fog.
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Cephalon, Meetings, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, Top News, tagged Cephalon, nuvigil on March 30, 2010|
*****
TODAY’S NEWS
Patenting genes called into question. Frankly, this is a legal/medical/sociological discussion that needs to happen.
Cephalon‘s jet lag indication on Nuvigil may be stuck on the runway for a while.
When companies – and agencies – can’t count. An expensively amusing tale.
The Top 20 Drugmakers, listed.
Another experimental cancer drug hits the wall. That’s two in two days. Bummer.
RECOMMENDED
POA/Sales Meeting Training – If you are responsible for training during periodic “live” meetings, let’s discuss the programs you’re looking for. The Impactiviti partner network can undoubtedly help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
The latest Impactiviti Connection e-newsletter is up! You can subscribe here.
PLUS
Huw Tippett, head of global sales for Novartis, explains his firm’s new focus on creating customer value and unlocking value from key accounts – Why Pharma Needs a New Commercial Model.
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Oncology, Pharma, Pharma News, Pharmaceutical, Roche, Top News, tagged Abraxane, Abraxis, Ratiopharm, Teva on March 18, 2010|
*****
TODAY’S NEWS
It appears that the 3-way bidding war for Ratiopharm is going to be won by Teva. So, who will Pfizer go after next?
Abraxis jumps after successful lung cancer comparative trial – The Abraxis product, Abraxane, combines paclitaxel with a human protein to administer it in higher doses, according to company data. During the trial, in the third of three phases generally required for regulatory approval of a medicine, Abraxane showed a more successful response rate in treating non- small cell lung cancer than paclitaxel…more
Roche bullish on some pipeline drugs for cancer and cholesterol – The chief executive of Roche Holding AG said on Wednesday the Swiss drugmaker’s experimental drugs to treat melanoma and raise “good” HDL cholesterol could transform treatment of cancer and heart disease. In an interview, Roche Chief Executive Officer Severin Schwan said its drug designed to raise good cholesterol, called dalcetrapib, “could be a game changer in how we treat lipid diseases,” noting it is being tested in 15,000 patients in partnership with Japan Tobacco Inc…more
RECOMMENDED
Presentation skills – Your employees need training on more effective presenting. Impactiviti’s vendor/partners have just what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Being purpose-full. Can you state your purpose in one minute or less to that person in the mirror?
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
*****
Posted in Amylin, Novartis, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical, Roche, Top News, tagged Amylin, Byetta, cystic fibroses, Novartis, Pfizer, Sutent on March 8, 2010|
*****
TODAY’S NEWS
New experimental RA/Lupus drug suspended after patient deaths – Swiss drugmaker Roche Holding AG and U.S. biotechnology company Biogen Idec are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s future…more
So, what about Amylin‘s Byetta? The pundits are dueling as potential once-a-week version approval draws near…
An interesting background story on Pfizer‘s expensive oncology “miracle” drug Sutent.
RECOMMENDED
Training new (or experienced) brand managers? – We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
A “trifecta” social media approach – Novartis sponsors a community, Twitter account, and Facebook Fan Page for Cystic Fibrosis patients. How are they doing? An Impactiviti review.
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
***
Impactiviti blog 